drugset
drugset / Trial / NCT02231723

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

NCT02231723 ↗

Phase 1 Completed 139 enrolled Sumitomo Pharma America, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.

Timeline

Start
2014-08
Primary completion
2020-06
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Napabucasin Small molecule — Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous
Background Irinotecan Small molecule 165 mg/m2 Intravenous
Background Irinotecan Sucrosofate Other / unclassified 70 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Paclitaxel Small molecule 125 mg/m2 Intravenous
Background fluorouracil Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

pancreatic adenocarcinoma